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ABSTRACT Metabolites of human or microbial origin have the potential to be im-
portant biomarkers of the disease state in cystic ﬁbrosis (CF). Clinical sample collec-
tion and storage conditions may impact metabolite abundances with clinical rele-
vance. We measured the change in metabolite composition based on untargeted
gas chromatography-mass spectrometry (GC-MS) when CF sputum samples were
stored at 4°C, 20°C, or 80°C with one or two freeze-thaw cycles. Daily measure-
ments were taken for 1 week and then weekly for 4 weeks (4°C) and 8 weeks
(20°C). The metabolites in samples stored at 20°C maintained abundances similar
to those found at80°C over the course of 8 weeks (average change in Bray-Curtis
distance, 0.06  0.04) and were also stable after one or two freeze-thaw cycles.
However, the metabolite proﬁles of samples stored at 4°C shifted after 1 day and
continued to change over the course of 4 weeks (average change in Bray-Curtis dis-
tance, 0.31  0.12). The abundances of several amino acids and other metabolites
increased with time of storage at 4°C but remained constant at 20°C. Storage tem-
perature was a signiﬁcant factor driving the metabolite composition (permutational
multivariate analysis of variance: r2  0.32 to 0.49, P  0.001). CF sputum samples
stored at 20°C at the time of sampling maintain a relatively stable untargeted
GC-MS proﬁle. Samples should be frozen on the day of collection, as more than 1
day at 4°C impacts the global composition of the metabolites in the sample.
IMPORTANCE Metabolomics has great potential for uncovering biomarkers of the
disease state in CF and many other contexts. However, sample storage timing and
temperature may alter the abundance of clinically relevant metabolites. To assess
whether existing samples are stable and to direct future study design, we conducted
untargeted GC-MS metabolomic analysis of CF sputum samples after one or two
freeze-thaw cycles and storage at 4°C and 20°C for 4 to 8 weeks. Overall, storage
at 20°C and freeze-thaw cycles had little impact on metabolite proﬁles; however,
storage at 4°C shifted metabolite abundances signiﬁcantly. GC-MS proﬁling will aid
in our understanding of the CF lung, but care should be taken in studies using spu-
tum samples to ensure that samples are properly stored.
KEYWORDS biomarkers, metabolomics, microbial metabolites, microbiome,
reproducibility, sample storage
The staggering metabolic complexity of any human biological specimen results fromboth human and microbial metabolism and could provide clinically relevant bio-
markers of disease. Recent studies based on chromatography and mass spectroscopy
have estimated that tens or hundreds of thousands of distinct metabolites are in
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human biological specimens and that a third to half of them are produced or altered
by microbes (1, 2). In this study, we assessed the impact of storage temperature and
time on the metabolite composition of sputum samples collected from people with
cystic ﬁbrosis (CF). CF is a genetic disease caused by a mutation in a cellular ion transporter
that results in increased susceptibility of the respiratory tract to bacterial infection (3–5). The
lives of persons with CF are punctuated by periods of worsened respiratory symptoms
referred to as pulmonary exacerbations. Although the etiology of these events remains
unclear, changes in the structure and/or activity of airway microbial communities are
believed to play a role (6–12). Decades of study of the microbiology of CF airway infection
have relied on the recovery of selected bacterial species in culture of respiratory specimens.
More recently, next-generation DNA sequencing and metabolomic analyses have contrib-
uted to a broader appreciation of the complexity and dynamics of the microbial ecology of
CF airways (6, 7, 13). Culture-independent approaches have the potential to identify
changes in microbial community structure and activity associated with pulmonary exacer-
bations, thereby offering insight that may lead to novel approaches to the prevention or
better treatment of these episodes (14–17).
The utility of metabolomics in advancing our understanding of CF exacerbations,
however, depends on an appreciation of how variables in sample handling may impact
measurements of global metabolic proﬁles and/or assessment of speciﬁc metabolites of
interest. Respiratory samples, including expectorated sputum and bronchoalveolar
lavage ﬂuid, are most often obtained from patients in clinical settings where immediate
freezing and storage are not practical. Samples may be kept at 4°C or20°C for various
periods of time before being stored at 80°C. Samples may also undergo repeated
cycles of freezing and thawing prior to analysis. While studies have addressed the
impact of storage temperature on the metabolomic analysis of clinical samples such as
plasma and urine (18–20), comparable studies assessing sputum are lacking. We
previously examined the impact of storage conditions on CF sputum metabolomic
proﬁles based on liquid chromatography-mass spectrometry (LC-MS) and found that
proﬁles were stable in samples stored for at least 4 weeks at 20°C (21). While LC-MS
can be used to study low-molecular-weight compounds, it cannot ionize nonpolar
compounds and is not practical for analysis of volatile compounds, which are better
analyzed by gas chromatography (GC)-MS. With respect to CF, recent breath sampling
has shown that levels of the volatile compound 2,3-butanedione, a pH-neutral bacterial
fermentation product, were higher in the breath of CF patients than in that of healthy
individuals. Another compound from the same metabolic pathway, 2,3-butanediol, was
associated with increased virulence of the CF opportunistic pathogen Pseudomonas
aeruginosa in both culture-based and murine infection models (22–24). These studies
highlight the potential of metabolomic analysis for investigation of the microbiology of
airway infection in CF. A critical element of such studies, however, is a more complete
understanding of the impact of sample storage on measurements of metabolites
detected by GC-MS. In the study reported here, we assessed the stability of a wide
range of volatile metabolites in sputum samples stored at 4°C and 20°C for various
periods of time with one or two freeze-thaw cycles.
RESULTS
Bacterial community proﬁles. Bacterial 16S rRNA gene sequencing revealed similar
proﬁles in two sputum samples collected from two CF patients during the course of
routine medical care (Fig. 1). Prevotella and Pseudomonas dominated in both samples;
the distribution of microbes in these samples was typical of an adult CF airway
community.
Effect of storage at 4°C or20°C. Our goal was to determine the impact of storage
time and temperature on GC-MS metabolite proﬁles, as depicted in the ﬂowchart in
Fig. 2. Two sputum samples were split into 76 aliquots and stored at 4°C or20°C, with
2 additional aliquots stored immediately at 80°C; daily measurements were taken for
a week and then weekly for 4 weeks (4°C) or 8 weeks (20°C) (Fig. 2). GC-MS of each
sample was performed, and the resulting metabolomic proﬁles were visualized by
Wandro et al.
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principal-coordinate analysis (PCoA) (Fig. 3). A total of 239 metabolites were detected,
of which 104 were identiﬁable. A subset of molecules are represented in a heat map
depicting the fold change in metabolite intensity at each storage temperature over
time (see Fig. S1 and S2 in the supplemental material). For both patients, the samples
stored at 20°C clustered together with the respective time zero samples that were
stored immediately at 80°C, while samples stored at 4°C drifted in the ordination
space over time. Storage at 4°C versus 20°C was found to signiﬁcantly affect
the overall metabolite proﬁle (permutational multivariate analysis of variance
[PERMANOVA]: r2  0.49 [sample 1] and 0.32 [sample 2], P  0.001) (Table S1). Storage
at 4°C resulted in larger changes in metabolite abundance over time (Fig. S3). A major
contributor to the changing metabolite proﬁle at 4°C was the increasing total ion count
between days 1 and 28, which remained stable at 20°C (Fig. S4). The Bray-Curtis (BC)
distance of each metabolomic proﬁle from the time zero proﬁle was calculated for
FIG 2 Flowchart and study design schematic. Sputum samples from two patients were homogenized, aliquoted,
and stored at either 20°C or 4°C. Duplicates of stored samples were taken daily for a week, and weekly samples
were taken for 4 weeks at 4°C and 8 weeks at 20°C. At each time point, an additional replicate was subjected to
either one or two freeze-thaw cycles. The aliquots were all analyzed by untargeted GC-MS.
FIG 1 16S rRNA gene sequence proﬁles of the bacterial communities of the sputum samples aliquoted
for the storage study. The V4 region of the 16S rRNA gene was ampliﬁed, sequenced, and analyzed with
mothur as described previously (21). The relative abundances of the ﬁve most abundant taxa in each
sputum sample are shown.
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samples stored at 4°C or 20°C (Fig. 4). After 1 day, the metabolomic proﬁles of
samples stored at 4°C were observed to be more distant than those of samples stored
at 20°C and the average distance from the time zero proﬁle increased each week in
samples stored at 4°C. The average distance of the metabolomic proﬁles of the samples
stored at 20°C from the time zero proﬁle remained steady over the course of 8 weeks
(average change in BC distance, 0.06  0.04), indicating that the overall metabolite
proﬁle did not change with storage at 20°C. In contrast, the metabolite proﬁles of
samples stored at 4°C continued to change over the course of 4 weeks (average change
in BC distance, 0.31  0.12).
Metabolites distinguishing patient samples. The samples collected from each
patient clustered separately along the primary PCoA axis (Fig. 3), indicating that the two
patients’ sputum samples had unique metabolomics proﬁles. The metabolites that
differed the most between the samples from patients 1 and 2 as determined by
supervised random-forest analysis and ranked by the mean decrease in predictive
accuracy were putrescine, xylitol, glycerol, 5-aminovaleric acid, and uric acid (Fig. 5A).
Metabolites that change with storage temperature and time. The metabolite
proﬁles of sputum samples from both patients stored at 4°C for various lengths of time
separate along the secondary PCoA axis, indicating common changes in the overall
metabolomic proﬁle with storage at this temperature (Fig. 3). A supervised random-
forest analysis was used to determine which metabolites were responsible for the
FIG 3 PCoA of BC distances calculated from the metabolite abundances in each sample. The percent
variance explained by each axis is shown in parentheses in each axis label. Aliquots of the sample from
patient 1 are shown as circles, while those of the sample from patient 2 are depicted as triangles. The
gold standard 80°C samples are represented by solid black circles, while 20°C samples are repre-
sented by gray circles and 4°C samples are represented by open circles. The size of the symbol reﬂects
the storage time, with later times represented by smaller symbols.
FIG 4 Effect of storage at20°C versus 4°C. BC distances between samples at each storage temperature
and the corresponding patient samples stored immediately at80°C are shown. All replicates from both
samples are shown, including those subjected to one or two freeze-thaw cycles.
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differences between samples stored at 4°C and those stored at20°C. The top variables
of importance (VIPs) separating samples collected at different temperatures are shown
in Fig. 5B. Many of the metabolites that were the most different at each storage
temperature were amino acids (Fig. 5B and C). The intensities of the VIP metabolites at
each time point are shown in Fig. 5C and indicate that the amino acids increased in
abundance with time at 4°C and stayed more constant at 20°C.
Clear trends showing either an increase or a decrease over time at either 4°C or
20°C were not observed for several metabolites that have been determined to be
clinically relevant to CF in other studies, including lactic acid, putrescine, and
5-aminovaleric acid (Fig. 6).
Impact of freeze-thawing on metabolomic proﬁles. At each time point, samples
were assessed after being thawed once and again after a second freeze-thawing. The
differences between the overall metabolite proﬁles of samples thawed once and those
thawed twice were not statistically signiﬁcant (PERMANOVA: r2  0.005, P  0.72; see
Table S1).
Metabolite intensity and CV. The coefﬁcient of variation (CV  standard deviation/
mean) for each metabolite stored at either temperature was assessed (Fig. 7). The metab-
olites in aliquots stored at20°C had lower CVs than those stored at 4°C, as demonstrated
by the distribution of points in the violin plot in Fig. 7, where the CVs of the aliquots stored
at 20°C largely fall under 0.3 while the CVs of the aliquots stored at 4°C are more widely
FIG 5 The VIPs from a supervised random-forest analysis to determine which metabolites best distinguish (a) patient 1 and 2 samples
and (b) storage at 20°C versus storage at 4°C. All time points were included, and intensities were log transformed. (c) Intensities over
time of ﬁve metabolites that distinguish storage at the temperatures shown.
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distributed. The distribution of CVs for each metabolite during storage at20°C remained
about the same, regardless of whether the samples at20°C were stored for 28 or 56 days
or whether they were thawed once or twice (data not shown).
DISCUSSION
Metabolite proﬁling complements other culture-independent approaches, such as
bacterial 16S rRNA gene amplicon sequencing, in characterizing bacterial communities
in biological specimens. This could aid in the identiﬁcation of biomarkers of disease
progression that are believed to be associated with changes in the activity of host
microbial communities. In CF, for example, the production of fermentation products
such as lactic acid has been found to be an indicator of pulmonary exacerbation that
can be measured by GC-MS (12, 25, 26). Sample storage conditions can have a
signiﬁcant impact on the abundances of metabolites in biological samples, and studies
assessing metabolite proﬁles need to account for these effects. In previous work, we
observed that CF sputum sample metabolite proﬁles determined by LC-MS were
unstable after sample storage at 4°C (21).
In this study, we captured smaller, aqueous, and more volatile metabolites in CF
sputum by acetonitrile-isopropyl alcohol-water extraction, followed by untargeted
FIG 6 Intensities of several metabolites of potential clinical signiﬁcance after storage of samples from
patients 1 and 2 at 4°C or 20°C, including lactic acid (a), 5-aminovaleric acid (b), and the polyamine
putrescine (c).
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GC-MS. Unfortunately, some microbial fermentation products of interest, such as
2,3-butanedione and 2,3-butanediol, are extremely volatile and were not consistently
detectable by this approach. Proﬁles of two sputum samples stored at either 4°C or
20°C for various lengths of time were assessed. We observed that storage at 20°C
yielded stable metabolite proﬁles with variations in metabolite abundance similar to
those found in technical replicates. More speciﬁcally, the range of BC dissimilarity
values among samples stored at 80°C did not increase among samples stored at
20°C. In contrast, the BC distances of samples stored at 4°C increased signiﬁcantly
with storage time. Of note, however, some metabolites appeared to remain stable
during storage at 4°C, including some with potential as biomarkers of the CF clinical
disease state, such as lactic acid.
Interindividual variation is often the most signiﬁcant factor driving differences in
microbial or metabolite composition between biological specimens, although the
relative contributions of human and microbial metabolism to metabolite proﬁles are
often difﬁcult to distinguish. In this study, the metabolite proﬁles of samples from two
individuals were consistently distinct, with the unique features of each resulting in clear
demarcation by PCoA. Sample storage temperature also had a signiﬁcant impact on
metabolite proﬁles that was also apparent in PCoA. The impact of sample storage time
and temperature was apparent in an analysis of total metabolite intensity versus time
(Fig. S1); the total abundance of the metabolites being measured increased at 4°C but
not at 20°C. Overall, these results suggest either active microbial metabolism or
metabolite degradation in cells at 4°C, leading to increases in the intensity of com-
pounds detectable by GC, including amino acids and other cellular debris.
It is also possible that changes in bacterial community structure under different
storage conditions account for differences in metabolite abundance. Previous work has
shown, however, that differences in community structure between sputum sample
aliquots stored at room temperature and aliquots stored at other temperatures were
less than the differences observed between intra- and intersample controls (27). In
samples with communities not yet dominated by P. aeruginosa, a reduction in diversity
after storage at room temperature was observed (28).
We note that although this study involved GC-MS analysis of nearly 200 samples, it
was limited to two “parent” sputum samples from which dozens of aliquots were
obtained, variably stored, and analyzed. While we have no reason to believe that these
samples were atypical in any regard, previous work has shown that persons with CF
harbor distinct microbial communities, at least during the early and intermediate stages
of lung disease (6, 7). An analysis of metabolite stability (under various storage
conditions) in sputum samples from a greater number of individuals is required to
better demonstrate the generalizability of our ﬁndings.
In summary, storage of CF sputum samples at 4°C leads to changes in metabolite
FIG 7 Violin plot of the CVs of each metabolite with storage at 4°C or20°C. The CV was calculated over
time for each metabolite in each patient sample.
Storage Time and Temperature Impact Metabolomics
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proﬁles within a day, with greater variation in metabolite abundances and an increase in
the abundance of many of the metabolites, including several amino acids detected by
untargeted GC-MS proﬁling. Nevertheless, several metabolites of clinical interest remain
stable, including lactic acid, putrescine, and 5-aminovaleric acid. Our results suggest that CF
sputum samples stored at 20°C retain stable GC-MS proﬁles for as long as 2 months.
Freezing and thawing samples once or twice does not have a signiﬁcant effect on
metabolite intensities. These ﬁndings need to be considered in designing studies to assess
the metabolome of microbial communities in CF airways and other environments.
MATERIALS AND METHODS
Sputum collection, storage, and sequencing. CF sputum samples were collected spontaneously
from two patients during the course of routine medical care. Sample collection was approved by the
University of Michigan Institutional Review Board. Samples were kept on ice for up to 30 min prior to
processing. An equal volume of cold sterile water was added to each sample before mechanical
homogenization with a sterile tissue homogenizer (Omni International) on ice for 10 s. Each sample was
divided into 100-l aliquots, and duplicate or quadruplicate aliquots were stored at different tempera-
tures for various lengths of time before being stored at 80°C (Fig. 2). At each time point, two aliquots
stored at 20°C were thawed on ice for 30 min before being stored at 80°C.
The bacterial communities in both of the sputum samples stored continuously at 80°C were
characterized as described previously (21). In brief, the V4 region of the 16S rRNA gene was ampliﬁed,
sequenced, and analyzed with mothur (21).
Metabolite extraction and metabolomic proﬁling. A total of 156 sputum samples were shipped
frozen on dry ice to the West Coast Metabolomics Center at the University of California (UC) Davis for
untargeted GC-time of ﬂight proﬁling. Metabolites were extracted from 20 l of sputum with 1 ml of 3:3:2
acetonitrile-isopropyl alcohol-water before derivatization and GC-MS analysis by Fiehn Lab standard
operating procedures (29–31). Metabolites were identiﬁed by comparison to the BinBase database.
Metabolite intensities were normalized to the total intensity of the metabolites identiﬁed in each sample.
Intensities were reported for 239 metabolites, of which 104 could be identiﬁed.
Statistical analysis. PCoA based on BC distances was used to visualize differences between sample
metabolite proﬁles due to processing conditions. All analyses were done with R (3.2.5). PCoA was
performed by using the ape library. BC distance was calculated by using the vegdist function in the
vegan library. PERMANOVA was performed by using the Adonis test in the vegan package in R (32).
Random-forest analysis was carried out both with the randomForest package in R by using default
parameters (ntree  500) (33) and with the rfPermute package (34), from which the ﬁgures were
generated. Plots were made by using the ggplot2 and ggpubr libraries.
Data availability. GC-MS data have been deposited at http://datadryad.org/resource/doi:10.5061/
dryad.qh100.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mSystems.00100-17.
FIG S1, PDF ﬁle, 0.3 MB.
FIG S2, PDF ﬁle, 0.3 MB.
FIG S3, PDF ﬁle, 0.1 MB.
FIG S4, PDF ﬁle, 0.1 MB.
TABLE S1, DOCX ﬁle, 0.01 MB.
ACKNOWLEDGMENTS
We acknowledge the help of several people from the West Coast Metabolomics
Center at UC Davis, including Megan Showalter, Sili Fan, and Oliver Fiehn.
This work was supported by grants from the National Heart, Lung, and Blood
Institute (R56HL126754-01A1) to J.J.L. and K.W. and the Cystic Fibrosis Foundation to
J.J.L. K.W. is supported by a Gilead CF Research Scholars award (app_00b072) and a
pilot grant (DK097154) from the UC Davis West Coast Metabolomics Center, where
metabolomics data were collected.
REFERENCES
1. Dorrestein PC, Mazmanian SK, Knight R. 2014. Finding the missing links
among metabolites, microbes, and the host. Immunity 40:824–832.
https://doi.org/10.1016/j.immuni.2014.05.015.
2. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G.
2009. Metabolomics analysis reveals large effects of gut microﬂora on
mammalian blood metabolites. Proc Natl Acad Sci U S A 106:3698–3703.
https://doi.org/10.1073/pnas.0812874106.
3. Quinton PM. 1983. Chloride impermeability in cystic ﬁbrosis. Nature
301:421–422. https://doi.org/10.1038/301421a0.
4. Quinton PM. 2008. Cystic ﬁbrosis: impaired bicarbonate secretion and
Wandro et al.
November/December 2017 Volume 2 Issue 6 e00100-17 msystems.asm.org 8
mucoviscidosis. Lancet372:415–417.https://doi.org/10.1016/S0140-6736
(08)61162-9.
5. Stoltz DA, Meyerholz DK, Welsh MJ. 2015. Origins of cystic ﬁbrosis lung
disease. N Engl J Med 372:351–362. https://doi.org/10.1056/NEJMra
1300109.
6. Carmody LA, Zhao J, Kalikin LM, LeBar W, Simon RH, Venkataraman A,
Schmidt TM, Abdo Z, Schloss PD, LiPuma JJ. 2015. The daily dynamics of
cystic ﬁbrosis airway microbiota during clinical stability and at exacer-
bation. Microbiome 3:12. https://doi.org/10.1186/s40168-015-0074-9.
7. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF,
Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, Young VB, LiPuma JJ.
2012. Decade-long bacterial community dynamics in cystic ﬁbrosis air-
ways. Proc Natl Acad Sci U S A 109:5809–5814. https://doi.org/10.1073/
pnas.1120577109.
8. Laguna TA, Reilly CS, Williams CB, Welchlin C, Wendt CH. 2015. Metabo-
lomics analysis identiﬁes novel plasma biomarkers of cystic ﬁbrosis
pulmonary exacerbation. Pediatr Pulmonol 50:869–877. https://doi.org/
10.1002/ppul.23225.
9. Lynch SV, Bruce KD. 2013. The cystic ﬁbrosis airway microbiome. Cold
Spring Harb Perspect Med 3:a009738. https://doi.org/10.1101/cshperspect
.a009738.
10. Smith DJ, Badrick AC, Zakrzewski M, Krause L, Bell SC, Anderson GJ, Reid
DW. 2014. Pyrosequencing reveals transient cystic ﬁbrosis lung micro-
biome changes with intravenous antibiotics. Eur Respir J 44:922–930.
https://doi.org/10.1183/09031936.00203013.
11. Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TWV, Carroll MP,
Hoffman LR, Jones G, Allen CE, Patel N, Forbes B, Tuck A, Bruce KD. 2011.
Does bacterial density in cystic ﬁbrosis sputum increase prior to pulmo-
nary exacerbation? J Cyst Fibros 10:357–365. https://doi.org/10.1016/j
.jcf.2011.05.002.
12. Twomey KB, Alston M, An SQ, O’Connell OJ, McCarthy Y, Swarbreck D,
Febrer M, Dow JM, Plant BJ, Ryan RP. 2013. Microbiota and metabolite
proﬁling reveal speciﬁc alterations in bacterial community structure and
environment in the cystic ﬁbrosis airway during exacerbation. PLoS One
8:e82432. https://doi.org/10.1371/journal.pone.0082432.
13. Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG,
Sogin ML, O’Toole GA. 2013. Unique microbial communities persist in
individual cystic ﬁbrosis patients throughout a clinical exacerbation.
Microbiome 1:27. http://www.microbiomejournal.com/content/1/1/27/
abstract.
14. Robroeks CMHHT, van Berkel JJBN, Dallinga JW, Jöbsis Q, Zimmermann
LJI, Hendriks HJE, Wouters MFM, van der Grinten CPM, van de Kant KDG,
van Schooten FJ, Dompeling E. 2010. Metabolomics of volatile organic
compounds in cystic ﬁbrosis patients and controls. Pediatr Res 68:75–80.
https://doi.org/10.1203/PDR.0b013e3181df4ea0.
15. Bos LDJ, Sterk PJ, Schultz MJ. 2013. Volatile metabolites of pathogens: a
systematic review. PLoS Pathog 9:e1003311. https://doi.org/10.1371/
journal.ppat.1003311.
16. Bos LDJ, Weda H, Wang Y, Knobel HH, Nijsen TME, Vink TJ, Zwinderman
AH, Sterk PJ, Schultz MJ. 2014. Exhaled breath metabolomics as a
noninvasive diagnostic tool for acute respiratory distress syndrome. Eur
Respir J 44:188–197. https://doi.org/10.1183/09031936.00005614.
17. Bos LDJ, Meinardi S, Blake D, Whiteson K. 2016. Bacteria in the airways
of patients with cystic ﬁbrosis are genetically capable of producing VOCs
in breath. J Breath Res 10:047103. https://doi.org/10.1088/1752-7163/
10/4/047103.
18. Krug S, Kastenmüller G, Stückler F, Rist MJ, Skurk T, Sailer M, Rafﬂer J,
Römisch-Margl W, Adamski J, Prehn C, Frank T, Engel KH, Hofmann T, Luy
B, Zimmermann R, Moritz F, Schmitt-Kopplin P, Krumsiek J, Kremer W,
Huber F, Oeh U, Theis FJ, Szymczak W, Hauner H, Suhre K, Daniel H. 2012.
The dynamic range of the human metabolome revealed by challenges.
FASEB J 26:2607–2619. https://doi.org/10.1096/fj.11-198093.
19. Rist MJ, Muhle-Goll C, Görling B, Bub A, Heissler S, Watzl B, Luy B. 2013.
Inﬂuence of freezing and storage procedure on human urine samples in
NMR-based metabolomics. Metabolites 3:243–258. https://doi.org/10
.3390/metabo3020243.
20. Pinto J, Domingues MRM, Galhano E, Pita C, Almeida Mdo C, Carreira IM,
Gil AM. 2014. Human plasma stability during handling and storage:
impact on NMR metabolomics. Analyst 139:1168–1177. https://doi.org/
10.1039/c3an02188b.
21. Zhao J, Evans CR, Carmody LA, LiPuma JJ. 2015. Impact of storage condi-
tions on metabolite proﬁles of sputum samples from persons with cystic
ﬁbrosis. J Cyst Fibros 14:468–473. https://doi.org/10.1016/j.jcf.2015.02.004.
22. Venkataraman A, Rosenbaum MA, Perkins SD, Werner JJ, Angenent LT.
2011. Metabolite-based mutualism between Pseudomonas aeruginosa
PA14 and Enterobacter aerogenes enhances current generation in bio-
electrochemical systems. Energy Environ Sci 4:4550–4559. https://doi
.org/10.1039/c1ee01377g.
23. Venkataraman A, Rosenbaum MA, Werner JJ, Winans SC, Angenent LT.
2014. Metabolite transfer with the fermentation product 2,3-butanediol
enhances virulence by Pseudomonas aeruginosa. ISME J 8:1210–1220.
https://doi.org/10.1038/ismej.2013.232.
24. Whiteson KL, Meinardi S, Lim YW, Schmieder R, Maughan H, Quinn R,
Blake DR, Conrad D, Rohwer F. 2014. Breath gas metabolites and bac-
terial metagenomes from cystic ﬁbrosis airways indicate active pH neu-
tral 2,3-butanedione fermentation. ISME J 8:1247–1258. https://doi.org/
10.1038/ismej.2013.229.
25. Zang X, Monge ME, McCarty NA, Stecenko AA, Fernández FM. 2017. Feasi-
bility of early detection of cystic ﬁbrosis acute pulmonary exacerbations by
exhaled breath condensate metabolomics: a pilot study. J Proteome Res
16:550–558. https://doi.org/10.1021/acs.jproteome.6b00675.
26. Tate S, MacGregor G, Davis M, Innes JA, Greening AP. 2002. Airways in
cystic ﬁbrosis are acidiﬁed: detection by exhaled breath condensate.
Thorax 57:926–929. https://doi.org/10.1136/thorax.57.11.926.
27. Zhao J, Li J, Schloss PD, Kalikin LM, Raymond TA, Petrosino JF, Young VB,
LiPuma JJ. 2011. Effect of sample storage conditions on culture-
independent bacterial community measures in cystic ﬁbrosis sputum
specimens. J Clin Microbiol 49:3717–3718. https://doi.org/10.1128/JCM
.01189-11.
28. Cuthbertson L, Rogers GB, Walker AW, Oliver A, Haﬁz T, Hoffman LR,
Carroll MP, Parkhill J, Bruce KD, van der Gast CJ. 2014. Time between
collection and storage signiﬁcantly inﬂuences bacterial sequence com-
position in sputum samples from cystic ﬁbrosis respiratory infections. J
Clin Microbiol 52:3011–3016. https://doi.org/10.1128/JCM.00764-14.
29. Cajka T, Fiehn O. 2016. Toward merging untargeted and targeted meth-
ods in mass spectrometry-based metabolomics and lipidomics. Anal
Chem 88:524–545. https://doi.org/10.1021/acs.analchem.5b04491.
30. Kind T, Tsugawa H, Cajka T, Ma Y, Lai Z, Mehta SS, Wohlgemuth G,
Barupal DK, Showalter MR, Arita M, Fiehn O. 24 April 2017. Identiﬁcation
of small molecules using accurate mass MS/MS search. Mass Spectrom
Rev. https://doi.org/10.1002/mas.21535.
31. Kind T, Wohlgemuth G, Lee DY, Lu Y, Palazoglu M, Shahbaz S, Fiehn O.
2009. FiehnLib—mass spectral and retention index libraries for metabo-
lomics based on quadrupole and time of ﬂight gas chromatography/
mass spectrometry. Anal Chem 81:10038–10048. https://doi.org/10
.1021/ac9019522.
32. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin PR, O’Hara RB,
Simpson GL, Solymos P, Stevens MHH, Wagner H. 2015. Vegan: commu-
nity ecology package. R package version 2.3-5.2016. R Foundation for
Statistical Computing, Vienna, Austria. https://cran.r-project.org/web/
packages/vegan/index.html.
33. Liaw A, Wiener M. 2002. Classiﬁcation and regression by randomForest.
R News 2:18–22.
34. Archer E. 2016. Estimate permutation P-values for random forest impor-
tance metrics. Package rfPermute. https://github.com/EricArcher/rfPermute.
Storage Time and Temperature Impact Metabolomics
November/December 2017 Volume 2 Issue 6 e00100-17 msystems.asm.org 9
